Peritoneal metastasis of gastric cancer
Conditions
Interventions
A:Peritoneal exploration + rmhTNF intraperitoneal perfusion for 2 times + 6 cycles of systemic chemotherapy
B:Peritoneal exploration + paclitaxel intraperitoneal perfusion for 1 time + 6 cycles of systemic chemotherapy
C:Peritoneal exploration + rmhTNF intraperitoneal perfusion for 2 times + paclitaxel intraperitoneal perfusion for 1 time + systemic chemotherapy for 6 cycles
Sponsors
Beijing Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Pathologically confirmed gastric adenocarcinoma, positive peritoneal metastasis of gastric cancer or positive exfoliated cells of gastric cancer were detected in peritoneal lavage fluid during peritoneal exploration. (2) Aged 18-75 years; (3) Male or non-pregnant or lactating women; (4) Bone marrow reserve function is good, blood routine meets the following conditions: white blood cell (>3.5 *10^9/L), neutrophil (>1.5 *10^9/L), platelet(>100 *10^9/L), hemoglobin (>90 g/L); (5) Good organ function, biochemical examination met the following conditions: ALT < 2.5 * ULN, AST < 2.5 * ULN, serum total bilirubin < 1.5 * ULN, serum creatinine < 1.5 * ULN; (6) ECOG <= 1; (7) Voluntary signing of informed consent.
Exclusion criteria
Exclusion criteria: (1) Drug allergy history of TNF and its derivatives; (2) There is a history of other malignant tumors within 5 years. (3) Patients with severe or uncontrolled medical diseases and infections (including atrial fibrillation, angina pectoris, cardiac insufficiency, ejection fraction less than 50%, uncontrollable hypertension, body temperature > 38 C, etc.); (4) Patients who need to be treated for epileptic seizures (e.g. steroids or antiepileptic therapy); (5) Patients with severe or uncontrollable mental illness; (6) Drug abuse and medical, psychological or social conditions may interfere with patients'participation in research or influence the evaluation of research results; (7) Any unstable condition or situation that may endanger patient's safety and compliance; (8) Receiving anticancer drugs from other clinical trials; (9) Researchers believe that patients should not participate in other situations of the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1 years OS; | — |
Countries
China
Contacts
Public ContactWu Xiaojiang
Beijing Cancer Hospital
Outcome results
None listed